 |
|
Regression of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A Case With a 2-Year Follow-up Without a Prophylactic Colectomy
Kyu Young Kim, Seong Woo Jeon, Jung Gil Park, Chung Hoon Yu, Se Young Jang, Jae Kwang Lee, Hee Young Hwang
Ann Coloproctol. 2014;30(4):201-204. Published online 2014 Aug 26 DOI: https://doi.org/10.3393/ac.2014.30.4.201
|
|
Citations to this article as recorded by
 Surgical Decision-Making in Familial Adenomatous Polyposis
Allie E. Steinberger, Maggie L. Westfal, Paul E. Wise
Clinics in Colon and Rectal Surgery.2024; 37(03): 191. CrossRef Chemoprevention in hereditary digestive neoplasia: A comprehensive review
Eugénie Chevalier, Robert Benamouzig
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef Cancer-preventive Properties of an Anthocyanin-enriched Sweet Potato in the APCMINMouse Model
Khalid Asadi, Lynnette R. Ferguson, Martin Philpott, Nishi Karunasinghe
Journal of Cancer Prevention.2017; 22(3): 135. CrossRef Endogenous conversion of ω-6 to ω-3 polyunsaturated fatty acids infat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/β-catenin signaling or activating 15-PGDH/IL-18
Young-Min Han, Jong-Min Park, Ji-Young Cha, Migyeong Jeong, Eun-Jin Go, Ki Baik Hahm
International Journal of Cancer.2016; 138(9): 2247. CrossRef NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties
Khosrow Kashfi, Mitali Chattopadhyay, Ravinder Kodela
Redox Biology.2015; 6: 287. CrossRef Sulindac
Reactions Weekly.2015; 1570(1): 198. CrossRef
|